Skip to main contentAI and Advanced
/
ALEMBICLTD · NSEMarket ticker unavailable · configure an authorised index feed
AL
NSE · Equity shares · Biotechnology & Drugs-1.10 · -1.10%
Alembic ALEMBICLTD
NSE:INR 99
BSE:INR 88.61
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for ALEMBICLTD
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 100.1
Day rangeINR 97.4 — INR 101.57
52-week rangeINR 70.46 — INR 117.72
Volume7.08 L
Market cap2,279.71
P/E5.74
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)239.99
Net Income (INR Cr)317.38
Rev Growth (5 Year %)26.7
EPS Growth (5 Year %)-1.53
P/E Ratio5.74
Book Value95.22
EPS12.36
Price/BV1.04Computed
Research path: Interpret Alembic's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ALEMBICLTDAlembic1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,589.51 | 2,503 | 2,328.77 |
| Accumulated Depreciation Total | -23.4 | -21.28 | -20.95 |
| Cash Equivalents | 0 | 0 | Not available |
| Other Liabilities Total | 17.22 | 14.91 | 13.31 |
| Accrued Expenses | 0.5 | 0.3 | 0.25 |
| Long Term Debt | 6.61 | 10.67 | 7.39 |
| Common Stock Total | 51.36 | 51.36 | 51.36 |
| Other Equity Total | 144.46 | 239.34 | 275.1 |
| Other Current Assets Total | 1.95 | 1.74 | 1.3 |
| Prepaid Expenses | 0.93 | 0.7 | 0.74 |
| Total Assets | 2,589.51 | 2,503 | 2,328.77 |
| Current Portof LT Debt/Capital Leases | 4.03 | 3.78 | 1.76 |
| Additional Paid-In Capital | 211.51 | 211.51 | 211.51 |
| Cash | 1.41 | 2.71 | 1.26 |
| Total Equity | 2,445.09 | 2,338.59 | 2,185.56 |
| Long Term Investments | 2,179.3 | 2,118.58 | 2,012.88 |
| Retained Earnings(Accumulated Deficit) | 2,037.76 | 1,836.39 | 1,647.6 |
| Total Common Shares Outstanding | 25.68 | 25.68 | 25.68 |
| Property/Plant/Equipment Total-Gross | 194.86 | 156.61 | 152.59 |
| Tangible Book Valueper Share Common Eq | 95.22 | 91.07 | 85.11 |
| Goodwill Net | 0.05 | 0.05 | 0.05 |
| Total Liabilities | 144.42 | 164.41 | 143.21 |
| Total Debt | 10.64 | 14.45 | 9.15 |
| Short Term Investments | 99.68 | 58.19 | 13.86 |
| Cashand Short Term Investments | 101.1 | 60.9 | 15.12 |
| Total Receivables Net | 37.71 | 35.74 | 22.57 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Deferred Income Tax | 19.29 | 28.37 | 32.19 |
| Accounts Receivable-Trade Net | 33.95 | 29.97 | 19.76 |
| Property/Plant/Equipment Total-Net | 171.45 | 135.33 | 131.64 |
| Total Current Liabilities | 101.3 | 110.47 | 90.32 |
| Total Inventory | 55.57 | 105.78 | 97.66 |
| Accounts Payable | 23.84 | 28.26 | 31.02 |
| Other Currentliabilities Total | 72.93 | 78.13 | 57.29 |
| Total Long Term Debt | 6.61 | 10.67 | 7.39 |
| Other Long Term Assets Total | 36.56 | 36.22 | 36.22 |
| Note Receivable-Long Term | 4.9 | 7.96 | 10.59 |
| Total Current Assets | 197.24 | 204.87 | 137.39 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.4
Price to Sale Ratio9.50
Growth
Debt 5Yr CAGR %107.49
Margins
Operating Margin 12m32.52
Operating Margin 5y Avg29.86
Net Profit Margin 12m52.47
Net Profit Margin 5y64.28
Yield
Dividend Yield %2.66
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk33.49
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,936.2 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,367.5 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,981.8 | 1.69 L | 72.73 | — |
| Cipla | INR 1,408.2 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,121.25 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 70.88%
- FII
- 1.25%
- MF
- 3.36%
- Other
- 27.87%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg - EquityBullsMarket news · 5 Jun 2026, 10:33 pm
Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg EquityBulls
Alembic Pharmaceuticals in Focus After Receiving USFDA Approval For Drug With $27 Million Market Opportunity - Trade BrainsMarket news · 5 Jun 2026, 3:15 pm
Alembic Pharmaceuticals in Focus After Receiving USFDA Approval For Drug With $27 Million Market Opportunity Trade Brains
Alembic Ltd Technical Momentum Shifts Amid Bearish Outlook - Markets MojoMarket news · 4 Jun 2026, 8:04 am
Alembic Ltd Technical Momentum Shifts Amid Bearish Outlook Markets Mojo
Alembic Ltd is Rated Sell by MarketsMOJO - Markets MojoMarket news · 3 Jun 2026, 10:54 am
Alembic Ltd is Rated Sell by MarketsMOJO Markets Mojo
Alembic Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 3 Jun 2026, 8:05 am
Alembic Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Alembic Ltd Technical Momentum Shifts Amid Bearish Outlook - Markets MojoMarket news · 2 Jun 2026, 10:58 am
Alembic Ltd Technical Momentum Shifts Amid Bearish Outlook Markets Mojo
Corporate actions
Events
- annual General MeetingAGM
- dividendRs.2.4000 per share(120%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsTo Consider other business matters.
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Alembic
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- ALEMBICLTD
- BSE Code
- 506235
Questions
Stock FAQ
What is the symbol and ISIN of Alembic?
Alembic has the symbol ALEMBICLTD and ISIN - INE426A01027.
What is the current price of Alembic?
Alembic is currently trading at INR 99.00.
What are the year high and year low of Alembic?
Alembic has a year high of INR 117.72 and a year low of INR 70.46.
What is the market capitalization of Alembic?
Alembic has a market capitalization of INR 2,279.71 crore.
What is the P/E ratio of Alembic?
Alembic has a P/E ratio of 5.74.
What is the dividend yield of Alembic?
Alembic has a dividend yield of 2.66%.
How is the financial performance of Alembic based on revenue, net income, and EPS?
Alembic has revenue of INR 239.99 crore, net income of INR 317.38 crore, and EPS of INR 12.35.
What is the book value of Alembic?
Alembic has a book value of INR 95.22.
What is the debt-to-equity ratio of Alembic?
Alembic has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Alembic?
Alembic has a price-to-book ratio of 1.04 and a price-to-sales ratio of 9.50.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.